Le gouvernement du Bénin a engagé le processus de mise en oeuvre du RAMU dans le but d’améliorer l’accessibilité fi nancière des populations à un paquet de base de soins de santé de qualité. Commencées en 2008, la réflexion, la préparation et la mise en oeuvre du RAMU au Bénin ont fa...it émerger des défi s et des questions divers au sein des acteurs impliqués dans le processus. Ces acteurs qui se retrouvent tant aux niveaux international, national et opérationnel, que dans les secteurs gouvernemental, non-gouvernemental et privé sont la cible principale de cette publication.
more
L’accessibilité géographique et financière constante des médicaments essentiels de qualité,
sûrs et efficaces aux populations est un objectif majeur des politiques pharmaceutiques
nationales.
Pour atteindre cet objectif, le Ministère de la Santé du Burkina Faso a mis en place un systèm...e
public d’approvisionnement en médicaments essentiels qui repose sur la Centrale d'Achat des
médicaments essentiels et consommables médicaux (CAMEG) et ses agences commerciales
régionales et sur les dépôts répartiteurs de districts (DRD) avec un système de recouvrement
des coûts des produits pharmaceutiques.
more
Web annex 6: Injectable prostaglandins versus
placebo or no treatment
Evidence to Decision Framework
This manual is addressed to health care providers dealing with Mycobacterium ulcerans disease (Buruli ulcer). The manual aims to achieve a better understanding of the disease, its clinical presentation and its surgical management. The manual is aimed particularly at district health care providers. A... comprehensive protocol, adapted to each form and stage of the disease, is presented together with comments on the levels of resources and capabilities necessary
to shorten the length of treatment, to prevent complications and to minimize undesired sequelae and thus to obtain the best possible outcome for each patient. Some sections include advice relevant to surgeons (e.g. relating to bone infection). However, the level to which particular comments are intended to apply should be clear from the context.
more
The Lancet Microbe Series Chagas Disease 2 Volume 5, Issue 10100946 October 2024
The Lancet Regional Health - Americas 2024;36: 100821 https://doi.org/10.1016/j.lana.2024.100821
Politique et plan stratégique intégré de lutte contre les maladies non transmissibles (PSIMNT) 2012-2015
Web annex 5: Oxytocin and ergometrine versus placebo or no treatment
Evidence to decision framework
March 2021
This report presents the key findings of the NFHS-5 survey in the National Capital Territory (NCT) of Delhi, followed by detailed tables and an appendix on sampling errors. The 2019-21 National Family Health Survey (NFHS-5), the fifth in the NFHS series, provides information on populatio...n, health, and nutrition for India and each state and union territory.
more
Les activités menées au cours de l'année 2022 ont été effectuées dans le cadre de la mise en œuvre de la stratégie de coopération OMS -Burundi 2019 – 2023 et en accord avec les quatre axes stratégiques qui soustendent le Budget-Programme 2022-2023.
Ce Budget-Programme (BP) est issu du 1...3ème Programme Général de Travail (PGT) de l’OMS (2019-
2024).
more
COVID-19 outbreak is associated with the generation of many types of infectious wastes, including infected masks, gloves and other protective equipment, together with a higher volume of general waste of the same nature.
ECDC Technical Report
In line with ECDC’s recommendations provided in the ’Risk Assessment of HTLV-1/2 transmission by tissue/cell transplantation’ dated 14 March 2012, this Directive replaces the term ‘incidence’ with ‘prevalence’ in the description of endemic areas of HTLV-1/2 i...nfection. According to the new requirements ‘HTLV-1 antibody testing must be performed for donors living in, or originating from high-prevalence areas or with sexual partners originating from those areas or where the donor’s parents originate from those areas’ and this applies to both donors of non-reproductive tissues and cells and reproductive cells.
ECDC contracted experts from the Institut Pasteur in Paris to systematically review the published evidence on the distribution of HTLV-1 infection prevalence throughout the world and to identify high-prevalence countries and areas.
more
PLoS Negl Trop Dis 13(10): e0007694. In 2005, the World Health Organization (WHO) recognized Chagas disease (CD; Trypanosoma cruzi infection) as a neglected tropical disease (NTD) [1] and included it into the global plan to combat NTDs [2]. The Target 3.3 of the United Nations Sustainable Developmen...t Goals (UN/SDG) aims at ending the epidemics of NTDs by 2030 [3]. Mother-to-child (congenital/connatal) transmission is currently the main mode of transmission of T. cruzi over blood transfusions and organ transplantations in vector-free areas within and outside Latin America (LA). Based on recent demonstrations that congenital transmission can be prevented [4–7], WHO has shifted its objective, in 2018, from control to elimination of congenital CD (cCD).
more